Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents
Introduction Promising early-phase clinical studies with immune checkpoint inhibitors (CPIs) given as monotherapy, and adoption of these agents in a number of indications and settings, have driven further investigation into the use of these agents in …